BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 17574416)

  • 1. Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitors.
    Lin R; Chiu G; Yu Y; Connolly PJ; Li S; Lu Y; Adams M; Fuentes-Pesquera AR; Emanuel SL; Greenberger LM
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4557-61. PubMed ID: 17574416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents.
    Lin R; Connolly PJ; Lu Y; Chiu G; Li S; Yu Y; Huang S; Li X; Emanuel SL; Middleton SA; Gruninger RH; Adams M; Fuentes-Pesquera AR; Greenberger LM
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4297-302. PubMed ID: 17532631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.
    Lin R; Connolly PJ; Huang S; Wetter SK; Lu Y; Murray WV; Emanuel SL; Gruninger RH; Fuentes-Pesquera AR; Rugg CA; Middleton SA; Jolliffe LK
    J Med Chem; 2005 Jun; 48(13):4208-11. PubMed ID: 15974571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation.
    Lin R; Lu Y; Wetter SK; Connolly PJ; Turchi IJ; Murray WV; Emanuel SL; Gruninger RH; Fuentes-Pesquera AR; Adams M; Pandey N; Moreno-Mazza S; Middleton SA; Jolliffe LK
    Bioorg Med Chem Lett; 2005 May; 15(9):2221-4. PubMed ID: 15837297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of novel 3,4-disubstituted pyrazoles for nanomedicine applications against malignant gliomas.
    Comes Franchini M; Bonini BF; Camaggi CM; Gentili D; Pession A; Rani M; Strocchi E
    Eur J Med Chem; 2010 May; 45(5):2024-33. PubMed ID: 20129719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
    Krystof V; Cankar P; Frysová I; Slouka J; Kontopidis G; Dzubák P; Hajdúch M; Srovnal J; de Azevedo WF; Orság M; Paprskárová M; Rolcík J; Látr A; Fischer PM; Strnad M
    J Med Chem; 2006 Nov; 49(22):6500-9. PubMed ID: 17064068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of 3,5-diaminoindazoles as cyclin-dependent kinase inhibitors.
    Lee J; Choi H; Kim KH; Jeong S; Park JW; Baek CS; Lee SH
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2292-5. PubMed ID: 18353638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors.
    McIntyre NA; McInnes C; Griffiths G; Barnett AL; Kontopidis G; Slawin AM; Jackson W; Thomas M; Zheleva DI; Wang S; Blake DG; Westwood NJ; Fischer PM
    J Med Chem; 2010 Mar; 53(5):2136-45. PubMed ID: 20146435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.
    Traquandi G; Ciomei M; Ballinari D; Casale E; Colombo N; Croci V; Fiorentini F; Isacchi A; Longo A; Mercurio C; Panzeri A; Pastori W; Pevarello P; Volpi D; Roussel P; Vulpetti A; Brasca MG
    J Med Chem; 2010 Mar; 53(5):2171-87. PubMed ID: 20141146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases.
    Braña MF; Cacho M; García ML; Mayoral EP; López B; de Pascual-Teresa B; Ramos A; Acero N; Llinares F; Muñoz-Mingarro D; Lozach O; Meijer L
    J Med Chem; 2005 Nov; 48(22):6843-54. PubMed ID: 16250643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
    Markwalder JA; Arnone MR; Benfield PA; Boisclair M; Burton CR; Chang CH; Cox SS; Czerniak PM; Dean CL; Doleniak D; Grafstrom R; Harrison BA; Kaltenbach RF; Nugiel DA; Rossi KA; Sherk SR; Sisk LM; Stouten P; Trainor GL; Worland P; Seitz SP
    J Med Chem; 2004 Nov; 47(24):5894-911. PubMed ID: 15537345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.
    Brasca MG; Albanese C; Alzani R; Amici R; Avanzi N; Ballinari D; Bischoff J; Borghi D; Casale E; Croci V; Fiorentini F; Isacchi A; Mercurio C; Nesi M; Orsini P; Pastori W; Pesenti E; Pevarello P; Roussel P; Varasi M; Volpi D; Vulpetti A; Ciomei M
    Bioorg Med Chem; 2010 Mar; 18(5):1844-53. PubMed ID: 20153204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors.
    Ibrahim DA; El-Metwally AM
    Eur J Med Chem; 2010 Mar; 45(3):1158-66. PubMed ID: 20045222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationships of novel 1-arylmethyl-3-aryl-1H-pyrazole-5-carbohydrazide hydrazone derivatives as potential agents against A549 lung cancer cells.
    Xia Y; Fan CD; Zhao BX; Zhao J; Shin DS; Miao JY
    Eur J Med Chem; 2008 Nov; 43(11):2347-53. PubMed ID: 18313806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and anti-tumor activities of novel pyrazolo[1,5-a]pyrimidines.
    Li J; Zhao YF; Zhao XL; Yuan XY; Gong P
    Arch Pharm (Weinheim); 2006 Nov; 339(11):593-7. PubMed ID: 17036367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and anti-tumor activities of some new pyridines and pyrazolo[1,5-a]pyrimidines.
    Ahmed OM; Mohamed MA; Ahmed RR; Ahmed SA
    Eur J Med Chem; 2009 Sep; 44(9):3519-23. PubMed ID: 19398146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and preliminary biological evaluation of novel ethyl 1-(2'-hydroxy-3'-aroxypropyl)-3-aryl-1H-pyrazole-5-carboxylate.
    Wei F; Zhao BX; Huang B; Zhang L; Sun CH; Dong WL; Shin DS; Miao JY
    Bioorg Med Chem Lett; 2006 Dec; 16(24):6342-7. PubMed ID: 17000107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of new potent anticancer pyrazoles with high FLT3 kinase inhibitory selectivity.
    El-Deeb IM; Lee SH
    Bioorg Med Chem; 2010 Jun; 18(11):3961-73. PubMed ID: 20472440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and cytotoxic activity of 2-methylimidazo[1,2-a]pyridine- and quinoline-substituted 2-aminopyrimidine derivatives.
    Vilchis-Reyes MA; Zentella A; Martínez-Urbina MA; Guzmán A; Vargas O; Ramírez Apan MT; Ventura Gallegos JL; Díaz E
    Eur J Med Chem; 2010 Jan; 45(1):379-86. PubMed ID: 19879023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, crystal structure and biological evaluation of novel 2-(5-(hydroxymethyl)-3-phenyl-1H-pyrazol-1-yl)-1-phenylethanol derivatives.
    Zheng LW; Zhu J; Zhao BX; Huang YH; Ding J; Miao JY
    Eur J Med Chem; 2010 Dec; 45(12):5792-9. PubMed ID: 20947221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.